Summary
A total of 42 patients with cerebral metastases of malignant melanoma were included in this study of the nitrosourea fotemustine. The treatment plan consisted of a 1-h i. v. infusion of 100 mg/m2 fotemustine every week for 3–4 weeks, followed by a 4- to 5-week rest period. Responding or stabilised patients then received 100 mg/m2 fotemustine every 3 weeks. Among the 39 evaluable patients, 2 complete responses and 9 partial responses were documented, leading to an overall response rate of 28.2%. Most of the responses were obtained in previously untreated patients and/or those presenting with a single cerebral metastasis. Toxicity was mild and mainly hematological, especially in patients previously treated by polychemotherapeutic regimen. Our study confirms the activity of fotemustine in cerebral metastases of disseminated malignant melanoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amer MH, Al-Sarraf M, Baker LH, Waitkevicius VK (1978) Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 42:660–668
Atkinson L (1978) Melanoma of the central nervous system. Aust NZ J Surg 48 (1):14–16
Avril M-F, Bonneterre J, Delaunay M, Grosshans E, Fumoleau P, Israel L, Bugat R, Namer M, Cupissol D, Kerbrat P, Montcuquet P, Arcaute V, Bizzari J-P (1989) Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma—experience of the French study group. American Society of Clinical Oncologists. San Francisco
Burke PJ, McCarthy WH, Milton GW (1971) Imidazole carboxamide therapy in advanced malignant melanoma. Cancer 27 (3):744–750
Gottlieb JA, Frei E III, Luce JK (1972) An evaluation of the management of patients with cerebral metastases from malignant melanoma. Cancer 29 (3):701–705
Hafstrom L, Jonsson PE, Stromblad LG (1980) Intracranial metastases of malignant melanoma treated by surgery. Cancer 46(9):2088–2090
Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Namer M, Avril MF, Lauvin R, Kerbrat P, Vilmer C, Bizzari JP (1988) Multicentric study of the nitrosourea fotemustine (S 10036) in advanced malignant melanoma (AMM) including patients with cerebral metastases. Neo-Adjuvant Chemother 169:787–790
Jacquillat C, Khayat D, Avril MF, Banzet P, Weil M, Fumoleau P, Namer M, Lauvin R, Kerbrat P, Vilmer C, Bizzari JP (1989) Brain metastasis of malignant melanoma: clinical activity of the nitrosourea fotemustine (S 10036). Abstract, 13th congress of the ESMO, Lugano, 1988, Cancer Chemother Phormacol 23 [Suppl]
Katz HR (1981) The relative effectiveness of radiation therapy, corticosteroids, and surgery in the management of melanoma metastatic to the central nervous system. Int J Radiat Oncol Biol Phys 7 (7):897–906
Kristjansen PEG, Hansen HH (1988) Brain metastases from small cell lung cancer treated with combination chemotherapy. Eur J Cancer Clin Oncol 24:545
Kolaric K, Roth A (1980) Treatment of metastatic brain tumors with the combination of 1-methyl-1-nitrosourea (MNU) and cyclophosphamide. J Cancer Res Clin Oncol 97: 193–197
Posner JB (1977) Management of central nervous system metastases. Semin Oncol 4 (1):81–91
Postmus PE, Haaxma-Reiche H, Sleijfer DTH, (1987) Highdose etoposide for central nervous system metastases of small cell lung cancer. Preliminary results. Eur J Resp dis 70 [Suppl 149]:65
Retsas S, Gershuny AR (1988) Central nervous system involvement in malignant melanoma. Cancer 61 (9):1926–1934
Rosner D, Nemoto T, Lane W (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58:832
Stridsklev IC, Hagen S, Klepp O (1984) Radiation therapy for brain metastases from malignant melanoma. Acta Radio Oncol 23 (4):231–235
Zimm S, Wampler GL, Stablein D, Hazra T, Young HF (1981) Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 48 (2): 384–394
Author information
Authors and Affiliations
Additional information
Others institutions involved in this trial: A. Bernadou, Hôtel Dieu, Paris; J. Clavier, CHR de Brest; M. Delaunay, Hôpital Pellegrin Tripode, Bordeaux; J. P. Escande, Hôpital Tarnier, Paris; P. Fargeot, Centre George François Leclerc, Dijon; P. Lauret, Hôpital Charles Nicolle, Rouen; R. Leblay, Hôpital Sud, Rennes; P. Litoux, CHR de Nantes; G. Lorette, Hôpital Trousseau, Tours; R. Metz, Centre Alexis Vautrin, Nancy; A. Monnier, CHR Boulloche, Montbelliard; M. Mousseau, CHR de la Tronche, Grenoble; J. P. Olivier, Hôpital Dupuytren, Limoges; R. Touraine, Hôpital Henri Mondor, Créteil; F. Truchetet, Hôpital de Thionville, France
Rights and permissions
About this article
Cite this article
Jacquillat, C., Khayat, D., Banzet, P. et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother. Pharmacol. 25, 263–266 (1990). https://doi.org/10.1007/BF00684883
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00684883